plans to comprehensively halt the production of its bio-pesticide subsidiary, namely Gofar
Bio-Pesticide, due to the continuous deficit of this bio-pesticide company.
We are pursuing partners to fund future development of this program which currently receives financial support from a number of organizations including the MDA, GoFAR
, and the Friedreich's Ataxia Research Alliance.
Nantong Jiangshan to acquire Thai agrochemical enterprise Ningbo Tide achieves remarkable performance in international market Anhui Guangxin tries IPO again Government purchasing: a double-edged sword China's first Agricultural Insurance Regulations issued China actively participates in development of FAO/WHO pesticide specifications Lier Chemical shuts down chlorpyrifos production lines Gofar
Bio-Pesticide's production halts Huilong sets foot in micro-credit industry to promote its development
Portions of this clinical trial are supported by a grant from the Italy based patient advocacy group GoFAR.
Repligen's FA program continues to be supported by strong relationships with and funding from non-profit organizations including GoFAR, Friedreich's Ataxia Research Alliance (FARA), the Muscular Dystrophy Association (MDA), the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) and the National Ataxia Foundation (NAF).
FARA is especially grateful in that regard to its advocacy partners of GoFAR
, the Muscular Dystrophy Association and the National Ataxia Foundation.
Our continued collaboration with FARA and GoFAR
provides access to a global network of scientific thought leaders and patients and partially funds the development of our Friedreich's ataxia program.
Repligen's research efforts have been partially funded with grants from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Alliance, GoFAR
and the National Ataxia Foundation.